At MedImmune, we focus on therapeutic proteins, monoclonal antibodies, and other next-generation molecules to attack a range of diseases – putting us at the forefront of biologics research and development.
Our research organization is accountable for disease biology and target discovery, predictive sciences, safety and toxicology, early biomarker and patient stratification research, drug discovery, and pre-clinical drug development. These activities span our key therapeutic areas.
MedImmune also has one of the most robust pipelines in the industry, with more than 120 research projects and product candidates in our portfolio. We aim to deliver promising new biologics to the market by continuing our leadership in the area of infectious diseases; playing a key role in inflammation, autoimmune and respiratory diseases, and cancer; and building on our expertise in other areas to create a world-class focus in neuroscience, cardiovascular, and metabolic diseases.
Together with AstraZeneca, we operate as one global R&D team and collaborate across many functions, including preclinical/clinical development and international commercialization, to prioritize our portfolio. The objective is to increase speed, quality, and cost-effectiveness — and focus on projects that we believe have the best chance of success.